Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) fell 4% during mid-day trading on Friday . The stock traded as low as $14.48 and last traded at $14.50. 4,560 shares changed hands during trading, a decline of 98% from the average session volume of 182,819 shares. The stock had previously closed at $15.11.
Analyst Ratings Changes
Separately, HC Wainwright lowered their price objective on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, November 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Repare Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $31.50.
Get
Repare Therapeutics alerts:
Repare Therapeutics Trading Down 2.6 %
The business's 50-day moving average is $15.53 and its two-hundred day moving average is $13.91. The stock has a market capitalization of $617.23 million, a PE ratio of -20.15 and a beta of 0.06.
Insider Buying and Selling
In related news, Director Davis Jerel sold 250,000 shares of the company's stock in a transaction on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the director now directly owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The sale was disclosed in a filing with the SEC, which can be accessed through
the SEC website. 33.60% of the stock is owned by corporate insiders.
Institutional Trading of Repare Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Bartlett & Co. LLC purchased a new position in Repare Therapeutics in the 2nd quarter valued at about $28,000. UBS Group AG boosted its position in Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock valued at $43,000 after buying an additional 739 shares during the last quarter. Bpifrance SA purchased a new position in Repare Therapeutics in the 2nd quarter valued at about $113,000. Tower Research Capital LLC TRC purchased a new position in Repare Therapeutics in the 3rd quarter valued at about $113,000. Finally, Fox Run Management L.L.C. purchased a new position in Repare Therapeutics in the 3rd quarter valued at about $143,000. 78.19% of the stock is owned by hedge funds and other institutional investors.
About Repare Therapeutics
(Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
See Also
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
